Theratechnologies Inc T.TH

All comers

[SPCEO1]

THTX as noted several times that the phase 1a will take anyone who meets their criteria for the trial. I am not sure if we new this already or not but Paul told a friend of mine that they will be checking the patients tumors after the test to determine if they were overexpressing sortilin. So, with a small number of patients involved, there is a chance that none of those accepted into the trial will have sortilin overexpressing tumors. Now, I have to believe the chances are still pretty good that some will have sortilin overexpressing tumors but there are no guarantees since they are not pre-screening patients to admit an assortment of expressing and non-expressing patients into the trial.

He also said that Dr, Rothenberg had done a deep dive into TH's science before joining and that he would be helpful in reducing risk in their clinical development and creating multiple pathway to win. I think it is important that Dr. Rothenberg joined because of the science  and not because he and Paul were fishing buddies from their time together at Pfizer.

[juniper88]

I did mention some time ago that Thera would do a test on the tumors to look for overexpression of Sort1.  About a year ago, I had that discussion with Christian about if a tumor achive sample could be used instead of a biopsy.  He said back then archival sample would be fine. I would believe that with these late stage cancer patients changes would be good that at least some would be

[jfm1330]

We knew that they would test afterward for sortilin expression, that may be part of the delay to get results because if there is efficacy, I am sure they will want to report it with correlation with sortilin expression. About the all comers aspect of the process, I think this is not a problem because Thera already knows that some advanced cancer types are overexpressing sortilin almost at 100%. So

[qwerty22]

The way I look at this there are multiple things that have to go right for this technology to work out as a treatment in the clinic. One of those is whether the Sortilin receptor is a common or marginal receptor on tumours. The evidence is it prevalent in some cancers, they have to show that prevalence converts to patient responses. I remember in summer Christian talking about 75% of the

[SPCEO1]

Those seem like realistic expectations to me, outside of the hints that we have received that things might be better than that. The biggest hint to me so far is the addition of Dr. Rothenberg as I just cannot see him teaming up with TH if there were not some good indication of success in TH-1902's phase 1a trial. Dr. Beliveau's comments in that article/TV program were another good hint

[jfm1330]

My understanding is that MTD will be the dose where they see no more than one DLT event out of six patients treated at that dose, and that the dose above that had at least two DLT events. So, let's say they dis three patients at 420 mg/m2 without a DLT event (grade 2 toxicity is not a DLT event). So, after that, they went to 560 mg/m2 and they had two DLT event out of six patients or less. Now

[SPCEO1]

The info on the 560mg patient or patients, it was unclear to me as a second hand source if it was more than 1, came from TH in a conversation they had with a shareholder recently. It really was not very clear regarding any aspect of it other than something went on at the 560 level for at least a brief period of time. That may have occurred recently or may have happened at some earlier date. I don&

[Bucknelly21]

We have been thinking that for 2 months lol

[justus727]

This post has been removed in accordance with Community Policy